Harpoon Therapeutics Inc

NASDAQ:HARP   3:08:47 PM EDT
5.47
-0.01 (-0.18%)
Products, Regulatory

Harpoon Therapeutics Inc - Dose Escalation For Hpn217 (Bcma Tritac) Phase 1/2 Clinical Trial Ongoing

Published: 12/13/2021 22:36 GMT
Harpoon Therapeutics Inc (HARP) - Harpoon Therapeutics Provides Pipeline Update for Tritac® Clinical Programs and T Cell Engager Platforms.
Harpoon Therapeutics Inc - Dose Escalation for Hpn217 (bcma Tritac) Phase 1/2 Clinical Trial Ongoing.
Harpoon Therapeutics Inc - Ind-enabling Studies for Hpn601 (epcam Protritac) Are Progressing As Planned.